Effect of Aspirin augmentation on cognitive & clinical symptoms of schizophrenic patients

Introduction: schizophrenia is one of the most common psychological diseases. New investigations showed that NSAIDs usage could be helpful in its treatment by preventing PG sanitize with inhibiting cycloxygeniz activation. The aim of this study was to evaluate the affect of adding aspirin to regular schizophrenia treatment.
Methods: in this randomized clinical trial 40 schizophrenia patients who were admitted in Ibn Sina hospital and had the inclusion criteria were entered and fallowed up for 12 weeks. First group had received 1 gram aspirin and second group had received placebo with the same shap and color add on regular treatment of schizophrenia. Patient symptoms and signs and their side effects were compared with SPSS software using mann-whittny and t-test regard to the variables.
Results: patient`s mean age was 8.68± 31.9 year and 88.3 percent (33 patients) of them were male and 17.5%(7 patients) were female. Mean overall PANSS in aspirin group and placebo was 11.76±62.95 and 5.8±56.8in third week and 11.77± 60.15 and 6.63±53.8in sixth weeks and this difference were significant. (P=0.045, P=0.042) digit span and Wechsler showed no differences after intervention. (P>0.05)
Conclusion: adding aspirin to regular schizophrenia treatment could be helpful to control some signs and symptoms and reduce psychopathology.